BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 21968130)

  • 1. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
    Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
    J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA desensitization with bortezomib in a highly sensitized pediatric patient.
    May LJ; Yeh J; Maeda K; Tyan DB; Chen S; Kaufman BD; Bernstein D; Rosenthal DN; Hollander SA
    Pediatr Transplant; 2014 Dec; 18(8):E280-2. PubMed ID: 25174602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
    Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
    Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
    Weston M; Rolfe M; Haddad T; Lopez-Cepero M
    Clin Transpl; 2009; ():393-9. PubMed ID: 20524304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
    Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B
    Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor therapy for antibody-mediated rejection.
    Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
    Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.
    Lobashevsky AL; Higgins NG; Rosner KM; Mujtaba MA; Goggins WC; Taber TE
    Transplantation; 2013 Jul; 96(2):182-90. PubMed ID: 23778648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
    Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.